Paper

LBP-022-YI Single-dose of a novel monoclonal anti-HBV antibody (HepB mAb19) demonstrates sustained HBsAg suppression beyond 48 weeks: interim results from first-in-human phase I RUHBV1 and SAMBA trials

Journal of Hepatology · 2026 · Han Ngoc Le, Siri Nana Halling Svensgaard, Zijun Wang et al.